A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

Catriona M Turnbull; Paolo Marcarino; Tara A Sheldrake; Loretta Lazzarato; Clara Cena; Roberta Fruttero; Alberto Gasco; Sarah Fox; Ian L Megson; Adriano G Rossi

doi:10.1186/1476-9255-5-12

A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

Catriona M Turnbull, Paolo Marcarino, Tara A Sheldrake, Loretta Lazzarato, Clara Cena, Roberta Fruttero, Alberto Gasco, Sarah Fox, Ian L Megson, Adriano G Rossi

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory effects. Having previously shown that novel NO-aspirin hybrids containing a furoxan NO-releasing group have potent anti-platelet effects, here we investigate their anti-inflammatory properties. Here we examine their effects upon TNFalpha release from lipopolysaccharide (LPS)-stimulated human monocytes and monocyte-derived macrophages and investigate a potential mechanism of action through effects on LPS-stimulated nuclear factor-kappa B (NF-kappaB) activation.

Original language	English
Pages (from-to)	12
Journal	Journal of Inflammation (London, England)
Volume	5
DOIs	https://doi.org/10.1186/1476-9255-5-12
Publication status	Published - 31 Jul 2008

Access to Document

10.1186/1476-9255-5-12

Cite this

@article{5889dd6392f34f698fe1410d6c361eac,

title = "A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages",

abstract = "The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory effects. Having previously shown that novel NO-aspirin hybrids containing a furoxan NO-releasing group have potent anti-platelet effects, here we investigate their anti-inflammatory properties. Here we examine their effects upon TNFalpha release from lipopolysaccharide (LPS)-stimulated human monocytes and monocyte-derived macrophages and investigate a potential mechanism of action through effects on LPS-stimulated nuclear factor-kappa B (NF-kappaB) activation.",

author = "Turnbull, {Catriona M} and Paolo Marcarino and Sheldrake, {Tara A} and Loretta Lazzarato and Clara Cena and Roberta Fruttero and Alberto Gasco and Sarah Fox and Megson, {Ian L} and Rossi, {Adriano G}",

year = "2008",

month = jul,

day = "31",

doi = "10.1186/1476-9255-5-12",

language = "English",

volume = "5",

pages = "12",

journal = "Journal of Inflammation (London, England)",

issn = "1476-9255",

publisher = "Springer Nature",

}

TY - JOUR

T1 - A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

AU - Turnbull, Catriona M

AU - Marcarino, Paolo

AU - Sheldrake, Tara A

AU - Lazzarato, Loretta

AU - Cena, Clara

AU - Fruttero, Roberta

AU - Gasco, Alberto

AU - Fox, Sarah

AU - Megson, Ian L

AU - Rossi, Adriano G

PY - 2008/7/31

Y1 - 2008/7/31

N2 - The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory effects. Having previously shown that novel NO-aspirin hybrids containing a furoxan NO-releasing group have potent anti-platelet effects, here we investigate their anti-inflammatory properties. Here we examine their effects upon TNFalpha release from lipopolysaccharide (LPS)-stimulated human monocytes and monocyte-derived macrophages and investigate a potential mechanism of action through effects on LPS-stimulated nuclear factor-kappa B (NF-kappaB) activation.

AB - The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory effects. Having previously shown that novel NO-aspirin hybrids containing a furoxan NO-releasing group have potent anti-platelet effects, here we investigate their anti-inflammatory properties. Here we examine their effects upon TNFalpha release from lipopolysaccharide (LPS)-stimulated human monocytes and monocyte-derived macrophages and investigate a potential mechanism of action through effects on LPS-stimulated nuclear factor-kappa B (NF-kappaB) activation.

U2 - 10.1186/1476-9255-5-12

DO - 10.1186/1476-9255-5-12

M3 - Article

C2 - 18671842

SN - 1476-9255

VL - 5

SP - 12

JO - Journal of Inflammation (London, England)

JF - Journal of Inflammation (London, England)

ER -

A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

Abstract

Access to Document

Fingerprint

Cite this